Characteristics of randomized patients at diagnosis
| . | Arm A: imatinib (N = 56) . | Arm B: imatinib + Peg–IFN-α2b (N = 56) . | P . | ||
|---|---|---|---|---|---|
| Sex, % | .849 | ||||
| Male | 31 | (55.4) | 33 | (58.9) | |
| Female | 25 | (44.6) | 23 | (41.1) | |
| Median age, y (range) | 51 | (17-74) | 49 | (19-74) | .675 |
| White blood cells, × 109/L, median (range) | 92.2 | (1.5-411.0) | 83.7 | (4.6-285.0) | .880 |
| Platelets, × 109/L, median (range) | 376 | (102-1294) | 386 | (154-1236) | .359 |
| % blasts in peripheral blood, median (range) | 1.0 | (0.0-5.0) | 0.8 | (0.0-4.0) | .328 |
| Spleen (cm) below costal margin, median (range) | 0 | (0-20) | 0 | (0-11) | .758 |
| Median Sokal score (range) | 0.8 | (0.5-1.2) | 0.8 | (0.5-1.1) | .778 |
| . | Arm A: imatinib (N = 56) . | Arm B: imatinib + Peg–IFN-α2b (N = 56) . | P . | ||
|---|---|---|---|---|---|
| Sex, % | .849 | ||||
| Male | 31 | (55.4) | 33 | (58.9) | |
| Female | 25 | (44.6) | 23 | (41.1) | |
| Median age, y (range) | 51 | (17-74) | 49 | (19-74) | .675 |
| White blood cells, × 109/L, median (range) | 92.2 | (1.5-411.0) | 83.7 | (4.6-285.0) | .880 |
| Platelets, × 109/L, median (range) | 376 | (102-1294) | 386 | (154-1236) | .359 |
| % blasts in peripheral blood, median (range) | 1.0 | (0.0-5.0) | 0.8 | (0.0-4.0) | .328 |
| Spleen (cm) below costal margin, median (range) | 0 | (0-20) | 0 | (0-11) | .758 |
| Median Sokal score (range) | 0.8 | (0.5-1.2) | 0.8 | (0.5-1.1) | .778 |